Advertisement

Current Challenges with HDAC Inhibitor-Based Therapeutic Intervention Against Neurological Maladies

  • Shabir Ahmad Ganai
Chapter

Abstract

Histone deacetylase inhibitors (HDACi) have proved their mettle in treating hematological malignancies and are now emerging as propitious agents for tackling neurological complications. However, certain things limit their possible use as therapeutic agents for treating neuronal disorders. Thus this chapter details all the current therapeutic impediments in the pathway of HDACi. Among these roadblocks, lack of sufficient knowledge regarding the individual HDACs in neuronal diseases is one of the concerns, which is discussed. Further, this chapter sheds light on the lack of specificity of HDACi and high structural identity at the active sites of different HDACs. Importantly, the lack of blood-brain barrier permeability of HDACi restricting the use of these marvellous inhibitors against neurological disorders is detailed.

References

  1. Agis-Balboa RC, Pavelka Z, Kerimoglu C, Fischer A (2013) Loss of HDAC5 impairs memory function: implications for Alzheimer’s disease. J Alzheimers Dis 33(1):35–44CrossRefGoogle Scholar
  2. Alam MS, Getz M, Haldar K (2016) Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model. Sci Transl Med 8(326):326ra323CrossRefGoogle Scholar
  3. Bardai FH, Verma P, Smith C, Rawat V, Wang L, D’Mello SR (2013) Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity. J Neurosci 33(29):11833–11838CrossRefGoogle Scholar
  4. Bieliauskas AV, Pflum MKH (2008) Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 37(7):1402–1413CrossRefGoogle Scholar
  5. Chan TS, Tse E, Kwong Y-L (2017) Chidamide in the treatment of peripheral T-cell lymphoma. OncoTargets Ther 10:347–352CrossRefGoogle Scholar
  6. Ganai SA (2014) In silico approaches towards safe targeting of Class I histone deacetylases. In: Wells RD, Bond JS, Klinman J, Masters BSS, Bell E (eds) Molecular life sciences: an encyclopedic reference. Springer, New York, pp 1–9.  https://doi.org/10.1007/978-1-4614-6436-5_459-1 CrossRefGoogle Scholar
  7. Ganai SA (2018) Histone deacetylase inhibitors modulating non-epigenetic players: the novel mechanism for small molecule based therapeutic intervention. Curr Drug Targets 19(6):593–601CrossRefGoogle Scholar
  8. Grayson DR, Kundakovic M, Sharma RP (2010) Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 77(2):126–135CrossRefGoogle Scholar
  9. Guan J-S, Haggarty SJ, Giacometti E, Dannenberg J-H, Joseph N, Gao J, Nieland TJF, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenisch R, Tsai L-H (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459(7243):55–60CrossRefGoogle Scholar
  10. Hanson JE, La H, Plise E, Chen YH, Ding X, Hanania T, Sabath EV, Alexandrov V, Brunner D, Leahy E, Steiner P, Liu L, Scearce-Levie K, Zhou Q (2013) SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS One 8(7):e69964CrossRefGoogle Scholar
  11. Hooker JM, Kim SW, Alexoff D, Xu Y, Shea C, Reid A, Volkow N, Fowler JS (2010) Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography. ACS Chem Neurosci 1(1):65–73CrossRefGoogle Scholar
  12. Kim SW, Hooker JM, Otto N, Win K, Muench L, Shea C, Carter P, King P, Reid AE, Volkow ND, Fowler JS (2013) Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET. Nucl Med Biol 40(7):912–918CrossRefGoogle Scholar
  13. Rumbaugh G, Sillivan SE, Ozkan ED, Rojas CS, Hubbs CR, Aceti M, Kilgore M, Kudugunti S, Puthanveettil SV, Sweatt JD, Rusche J, Miller CA (2015) Pharmacological selectivity within Class I histone deacetylases predicts effects on synaptic function and memory rescue. Neuropsychopharmacology 40:2307CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Shabir Ahmad Ganai
    • 1
  1. 1.Division of Basic Sciences and Humanities, Faculty of AgricultureSKUAST-KashmirWadura SoporeIndia

Personalised recommendations